GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Pilla Reddy, Venkatesh  (2)
Material
Publisher
Person/Organisation
Language
Years
FID
  • 1
    In: CPT: Pharmacometrics & Systems Pharmacology, Wiley, Vol. 12, No. 1 ( 2023-01), p. 122-134
    Abstract: Combination therapy or concomitant drug administration can be associated with pharmacokinetic drug–drug interactions, increasing the risk of adverse drug events and reduced drug efficacy. Thus far, machine‐learning models have been developed that can classify drug–drug interactions. However, to enable quantification of the pharmacokinetic effects of a drug–drug interaction, regression‐based machine learning should be explored. Therefore, this study investigated the use of regression‐based machine learning to predict changes in drug exposure caused by pharmacokinetic drug–drug interactions. Fold changes in exposure relative to substrate drug monotherapy were collected from 120 clinical drug–drug interaction studies extracted from the Washington Drug Interaction Database and SimCYP compound library files. Drug characteristics (features) were collected such as structure, physicochemical properties, in vitro pharmacokinetic properties, cytochrome P450 metabolic activity, and population characteristics. Three different regression‐based supervised machine‐learning models were then applied to the prediction task: random forest, elastic net, and support vector regressor. Model performance was evaluated using fivefold cross‐validation. Strongest performance was observed with support vector regression, with 78% of predictions within twofold of the observed exposure changes. The results show that changes in drug exposure can be predicted with reasonable accuracy using regression‐based machine‐learning models trained on data available early in drug discovery. This has potential applications in enabling earlier drug–drug interaction risk assessment for new drug candidates.
    Type of Medium: Online Resource
    ISSN: 2163-8306 , 2163-8306
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2023
    detail.hit.zdb_id: 2697010-7
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: CPT: Pharmacometrics & Systems Pharmacology, Wiley, Vol. 11, No. 12 ( 2022-12), p. 1560-1568
    Abstract: The gold‐standard approach for modeling pharmacokinetic mediated drug–drug interactions is the use of physiologically‐based pharmacokinetic modeling and population pharmacokinetics. However, these models require extensive amounts of drug‐specific data generated from a wide variety of in vitro and in vivo models, which are later refined with clinical data and system‐specific parameters. Machine learning has the potential to be utilized for the prediction of drug–drug interactions much earlier in the drug discovery cycle, using inputs derived from, among others, chemical structure. This could lead to refined chemical designs in early drug discovery. Machine‐learning models have many advantages, such as the capacity to automate learning (increasing the speed and scalability of predictions), improved generalizability by learning from multicase historical data, and highlighting statistical and potentially clinically significant relationships between input variables. In contrast, the routinely used mechanistic models (physiologically‐based pharmacokinetic models and population pharmacokinetics) are currently considered more interpretable, reliable, and require a smaller sample size of data, although insights differ on a case‐by‐case basis. Therefore, they may be appropriate for later stages of drug–drug interaction assessment when more in vivo and clinical data are available. A combined approach of using mechanistic models to highlight features that can be used for training machine‐learning models may also be exploitable in the future to improve the performance of machine learning. In this review, we provide concepts, strategic considerations, and compare machine learning to mechanistic modeling for drug–drug interaction risk assessment across the stages of drug discovery and development.
    Type of Medium: Online Resource
    ISSN: 2163-8306 , 2163-8306
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2697010-7
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...